Neutralizing protease Nexin-1 in hemophilia patients on emicizumab improves thrombin generation

Neutralizing protease Nexin-1 in hemophilia patients on emicizumab improves thrombin generation

•Blocking PN-1 has been shown to control bleeding and improve hemostasis in hemophilia.•PN-1 blockade can accelerate the thrombin burst in blood from patients on emicizumab.•PN-1 blockade has no impact on fibrinolysis in blood from patients on emicizumab.•Patients receiving emicizumab may benefit fr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thrombosis research 2024-11, Vol.243, p.109174, Article 109174
Hauptverfasser: Arocas, Véronique, Venisse, Laurence, Boulaftali, Yacine, Loyau, Stéphane, Flaujac, Claire, de Raucourt, Emmanuelle, Bouton, Marie-Christine
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulant protein
Emicizumab
Hemophilia
Life Sciences
Serpin E2
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Blocking PN-1 has been shown to control bleeding and improve hemostasis in hemophilia.•PN-1 blockade can accelerate the thrombin burst in blood from patients on emicizumab.•PN-1 blockade has no impact on fibrinolysis in blood from patients on emicizumab.•Patients receiving emicizumab may benefit from PN-1 blockade to improve hemostasis.
ISSN:0049-3848
1879-2472
1879-2472
DOI:10.1016/j.thromres.2024.109174